SciDEX — Hypothesis Leaderboard

#	Hypothesis	Score	Dimensions	Market	Debates
🥇	Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment therapeutic • PVALB • Alzheimer's disease	1.000	Nov 0.78 Feas 0.86 Imp 0.80 Drug 0.75	0.964	2
🥈	Metabolic Reprogramming to Reverse Senescence therapeutic • SIRT1,PGC1A,NAMPT • —	1.000	Nov 0.60 Feas 0.90 Imp 0.82 Drug 0.90	0.980	2
🥉	SASP Modulation Rather Than Cell Elimination therapeutic • NFKB1,IL1B,BDNF • —	0.981	Nov 0.70 Feas 0.80 Imp 0.78 Drug 0.80	0.968	1
4	Closed-loop transcranial focused ultrasound targeting EC-II SST interneu therapeutic • SST • Alzheimer's disease	0.948	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.75	0.961	2
5	Closed-loop optogenetic targeting PV interneurons to restore theta-gamma therapeutic • PVALB • Alzheimer's disease	0.944	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.75	0.824	2
6	Closed-loop focused ultrasound targeting CA1 PV interneurons to restore therapeutic • PVALB • Alzheimer's disease	0.927	Nov 0.88 Feas 0.65 Imp 0.78 Drug 0.45	0.849	3
7	Closed-loop transcranial focused ultrasound targeting EC-II SST interneu therapeutic • SST • Alzheimer's disease	0.922	Nov 0.90 Feas 0.45 Imp 0.80 Drug 0.75	0.852	3
8	CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescenc therapeutic • CYP46A1 • neurodegeneration	0.921	Nov 0.75 Feas 0.60 Imp 0.80 Drug 0.55	0.801	1
9	Autophagy-Senescence Axis Therapeutic Window therapeutic • ATG7,BCL2,BCL2L1 • —	0.921	Nov 0.80 Feas 0.60 Imp 0.00 Drug 0.70	0.928	1
10	Selective Acid Sphingomyelinase Modulation Therapy therapeutic • SMPD1 • neurodegeneration	0.920	Nov 0.70 Feas 0.90 Imp 0.85 Drug 0.95	0.800	1
11	Palmitoylethanolamide-Based Endocannabinoid Therapy therapeutic • PPARA • —	0.919	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.90	0.799	2
12	CYP46A1 Overexpression Gene Therapy therapeutic • CYP46A1 • neurodegeneration	0.919	Nov 0.95 Feas 0.60 Imp 0.90 Drug 0.65	0.925	1
13	Closed-loop transcranial focused ultrasound to restore hippocampal gamma therapeutic • CCK • Alzheimer's disease	0.912	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.75	0.874	2
14	Closed-loop focused ultrasound targeting EC-II SST interneurons to resto therapeutic • SST • Alzheimer's disease	0.900	Nov 0.79 Feas 0.87 Imp 0.81 Drug 0.75	0.952	2
15	Closed-loop tACS targeting EC-II SST interneurons to block tau propagati therapeutic • SST • Alzheimer's disease	0.896	Nov 0.78 Feas 0.86 Imp 0.82 Drug 0.75	0.776	2
16	H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Prun therapeutic • TREM2 • neurodegeneration	0.887	Nov 0.65 Feas 0.82 Imp 0.75 Drug 0.80	0.897	1
17	Closed-loop tACS targeting EC-II PV interneurons to enhance perisomatic therapeutic • PVALB • Alzheimer's disease	0.867	Nov 0.78 Feas 0.65 Imp 0.75 Drug 0.45	0.811	2
18	Closed-loop focused ultrasound targeting EC-II PV interneurons to restor therapeutic • PVALB • Alzheimer's disease	0.863	Nov 0.85 Feas 0.45 Imp 0.75 Drug 0.30	0.885	3
19	Optogenetic restoration of hippocampal gamma oscillations via selective therapeutic • PVALB • Alzheimer's disease	0.863	Nov 0.78 Feas 0.45 Imp 0.68 Drug 0.35	0.811	3
20	Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 palmitoylat therapeutic • BDNF • Alzheimer's disease	0.861	Nov 0.82 Feas 0.70 Imp 0.83 Drug 0.68	0.811	3
21	Closed-loop transcranial focused ultrasound to restore hippocampal gamma therapeutic • PVALB • Alzheimer's disease	0.858	Nov 0.80 Feas 0.88 Imp 0.82 Drug 0.75	0.981	2
22	Closed-loop tACS targeting EC-II PV interneurons to suppress burst firin therapeutic • PVALB • Alzheimer's disease	0.857	Nov 0.78 Feas 0.87 Imp 0.81 Drug 0.75	0.918	2
23	Senescent Cell ASM-Complement Cascade Intervention therapeutic • SMPD1 • neurodegeneration	0.852	Nov 0.78 Feas 0.68 Imp 0.75 Drug 0.82	0.875	1
24	Gamma entrainment therapy to restore hippocampal-cortical synchrony therapeutic • SST • Alzheimer's disease	0.851	Nov 0.78 Feas 0.88 Imp 0.80 Drug 0.75	0.790	2
25	APOE-Dependent Autophagy Restoration therapeutic • MTOR • neurodegeneration	0.850	Nov 0.60 Feas 0.90 Imp 0.80 Drug 0.95	0.778	3
26	Optogenetic viral vector delivery via tFUS-mediated blood-brain barrier therapeutic • PVALB • Alzheimer's disease	0.846	Nov 0.90 Feas 0.45 Imp 0.80 Drug 0.30	0.870	2
27	Optogenetic restoration of hippocampal gamma oscillations via selective therapeutic • SST • Alzheimer's disease	0.845	Nov 0.80 Feas 0.45 Imp 0.70 Drug 0.25	0.867	2
28	Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurode therapeutic • SMPD3 • neurodegeneration	0.844	Nov 0.78 Feas 0.68 Imp 0.75 Drug 0.65	0.867	1
29	Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation therapeutic • HCRTR1/HCRTR2 • neurodegeneration	0.841	Nov 0.75 Feas 0.90 Imp 0.80 Drug 0.95	0.859	2
30	Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gam therapeutic • PVALB • Alzheimer's disease	0.831	Nov 0.79 Feas 0.86 Imp 0.80 Drug 0.75	0.933	2
31	Real-time gamma-guided transcranial focused ultrasound targeting EC-II S therapeutic • SST • Alzheimer's disease	0.827	Nov 0.82 Feas 0.35 Imp 0.78 Drug 0.25	0.782	3
32	Closed-loop transcranial focused ultrasound to restore hippocampal gamma therapeutic • PVALB • Alzheimer's disease	0.827	Nov 0.82 Feas 0.55 Imp 0.78 Drug 0.35	0.764	2
33	Beta-frequency entrainment therapy targeting PV interneuron-astrocyte co therapeutic • SST • Alzheimer's disease	0.827	Nov 0.82 Feas 0.85 Imp 0.82 Drug 0.75	0.892	2
34	Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preserv therapeutic • BDNF • Alzheimer's disease	0.820	Nov 0.68 Feas 0.72 Imp 0.78 Drug 0.68	0.700	2
35	Extracellular Vesicle Biogenesis Modulation therapeutic • CHMP4B • neurodegeneration	0.814	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.00	0.734	1
36	AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescu therapeutic • PRKAA1 • neurodegeneration	0.813	Nov 0.80 Feas 0.85 Imp 0.75 Drug 0.90	0.693	2
37	LRP1-Dependent Tau Uptake Disruption therapeutic • LRP1 • neurodegeneration	0.808	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.00	0.774	1
38	Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone Deficiency therapeutic • HCAR2 • neurodegeneration	0.808	Nov 0.70 Feas 0.82 Imp 0.75 Drug 0.88	0.832	1
39	Neutrophil Extracellular Trap (NET) Inhibition therapeutic • PADI4 • —	0.806	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.80	0.744	1
40	Dual-Receptor Antibody Shuttling therapeutic • — • Alzheimer's disease	0.803	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.00	0.866	1
41	Microglial TREM2-SYK Pathway Enhancement therapeutic • TREM2 • neurodegeneration	0.798	Nov 0.60 Feas 0.70 Imp 0.80 Drug 0.80	0.745	1
42	Closed-loop transcranial focused ultrasound targeting CA1 PV interneuron therapeutic • PVALB • Alzheimer's disease	0.797	Nov 0.92 Feas 0.35 Imp 0.78 Drug 0.25	0.823	2
43	CYP46A1 Suppression for Tau-Mediated Neurodegeneration therapeutic • CYP46A1 • neurodegeneration	0.792	Nov 0.75 Feas 0.45 Imp 0.70 Drug 0.65	0.818	1
44	Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Primi therapeutic • TLR4 • neurodegeneration	0.789	Nov 0.70 Feas 0.80 Imp 0.70 Drug 0.80	0.806	3
45	VCP-Mediated Autophagy Enhancement therapeutic • VCP • neurodegeneration	0.787	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.00	0.673	1
46	Closed-loop transcranial alternating current stimulation to restore hipp therapeutic • SST • Alzheimer's disease	0.785	Nov 0.78 Feas 0.88 Imp 0.81 Drug 0.75	0.856	2
47	Senescent Microglia Resolution via Maresins-Senolytics Combination therapeutic • BCL2L1 • neurodegeneration	0.784	Nov 0.80 Feas 0.70 Imp 0.80 Drug 0.80	0.664	2
48	Closed-loop tACS targeting entorhinal cortex layer II SST interneurons t therapeutic • SST • Alzheimer's disease	0.784	Nov 0.00 Feas 0.00 Imp 0.00 Drug 0.75	0.870	2
49	Selective HDAC3 Inhibition with Cognitive Enhancement therapeutic • HDAC3 • neurodegeneration	0.779	Nov 0.85 Feas 0.70 Imp 0.80 Drug 0.75	0.798	3
50	APOE4-Specific Proteolytic Fragment Inhibition Therapy therapeutic • APOE • Alzheimer's disease	0.777	Nov 0.80 Feas 0.45 Imp 0.70 Drug 0.35	0.757	1

🏆 Hypothesis Leaderboard

No results